Singh Prati Pal, Prakash Bhanu
Centre of Infectious Diseases; Department of Pharmacology and Toxicology; National Institute of Pharmaceutical Education and Research; S.A.S. Nagar, India.
Hum Vaccin Immunother. 2014;10(6):1747-51. doi: 10.4161/hv.28360. Epub 2014 Mar 14.
Globally, vaccines have emerged as one of the most effective, safe, and cost-effective public health interventions, and are known to save 2-3 million lives, annually. However, despite various commendable efforts, a suitable human malaria vaccine is yet to see the light of the day. The lack of our complete understanding of the molecular mechanisms of pathogenesis and immune protection in malaria appears to be responsible for this state. Earlier, our laboratory has reported that Swiss mice vaccinated with Plasmodium yoelii nigeriensis-total parasite antigens soluble in culture medium and saponin, following a 100% lethal challenge, showed 60% protection. The monoclonal antibodies (MAbs) generated from the splenocytes of these vaccinated/protected mice, following characterization by in vitro merozoite invasion inhibition assay, ex vivo macrophage phagocytosis assay, and in vivo passive transfer of protection test, belonged to 2 distinct groups-a larger group of MAbs inhibited<58% Mz invasion and transferred 30% passive protection, whereas a smaller group of MAbs inhibited 86% Mz invasion and transferred 60% passive protection. Additionally, the MAbs of the smaller group, as compared with the larger one, mediated nearly 2.4-fold enhanced macrophage phagocytosis of infected-erythrocytes, in vitro. These results thus clearly showed a dichotomy among the generated MAbs. An exploration of the phenomenon of dichotomy in protective immunity in malaria by using various hosts and malaria parasite combinations, especially at the level of antibodies, cells, and cytokines, may add new insights to our understanding of the protective immunity, and help in the identification of biomarkers/biosignatures of immune protection and development of future human malaria vaccines.
在全球范围内,疫苗已成为最有效、安全且具成本效益的公共卫生干预措施之一,据知每年可挽救200万至300万人的生命。然而,尽管付出了种种值得称赞的努力,一种合适的人类疟疾疫苗仍未问世。我们对疟疾发病机制和免疫保护分子机制的不完全了解似乎是造成这种状况的原因。此前,我们实验室报告称,用约氏疟原虫尼日尔株全寄生虫抗原(可溶于培养基和皂苷)接种的瑞士小鼠,在接受100%致死性攻击后,显示出60%的保护率。从这些接种/受保护小鼠的脾细胞中产生的单克隆抗体(MAb),经体外裂殖子入侵抑制试验、离体巨噬细胞吞噬试验和体内被动保护转移试验鉴定后,分为2个不同的组——一大组MAb抑制<58%的裂殖子入侵并转移30%的被动保护,而一小组MAb抑制86%的裂殖子入侵并转移60%的被动保护。此外,与大组相比,小组的MAb在体外介导的感染红细胞巨噬细胞吞噬作用增强了近2.4倍。因此,这些结果清楚地表明所产生的MAb之间存在二分法。利用各种宿主和疟原虫组合,特别是在抗体、细胞和细胞因子水平上,探索疟疾保护性免疫中的二分法现象,可能会为我们对保护性免疫的理解增添新的见解,并有助于识别免疫保护的生物标志物/生物特征以及开发未来的人类疟疾疫苗。